Clinical Trial Update: Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 [Phase 1]

View source ↗

Summary

Phase 1 study of autologous CD19-targeted CAR-T cells for precursor B-cell acute lymphoblastic leukemia. The trial status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• Autologous CD19-targeted CAR-T cell therapy

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING